Guselkumab for Plaque Psoriasis
(SPECTREM Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a treatment called guselkumab to evaluate its effectiveness for people with moderate plaque psoriasis, particularly in areas like the scalp, face, and genitals. Participants will receive either guselkumab (an injection) or a placebo (an inactive substance) as an injection. The trial seeks individuals who have had plaque psoriasis for at least six months and have tried at least one topical treatment without success. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to the potential availability of a new treatment.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop your current medications. However, it does mention that participants should not have used certain biologic drugs before. It's best to discuss your current medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that guselkumab is safe for treating plaque psoriasis. Studies have found that people using guselkumab for up to five years experienced positive results and tolerated it well. Unwanted side effects were similar to those expected with other psoriasis treatments. Most side effects were mild, such as colds or headaches. Overall, clinical trials support guselkumab's safety for people with moderate-to-severe plaque psoriasis.12345
Why do researchers think this study treatment might be promising for plaque psoriasis?
Guselkumab is unique because it specifically targets interleukin-23 (IL-23), a protein that plays a key role in the inflammation process of plaque psoriasis. Unlike many standard treatments, such as methotrexate or cyclosporine, which broadly suppress the immune system, guselkumab offers a more targeted approach, potentially reducing side effects. Researchers are excited about guselkumab because its targeted action not only promises effectiveness in reducing psoriasis symptoms but also enhances safety by minimizing the impact on the rest of the immune system.
What evidence suggests that guselkumab might be an effective treatment for plaque psoriasis?
Research has shown that guselkumab, which participants in this trial may receive, effectively treats plaque psoriasis. In clinical studies, patients experienced significant improvements in symptoms like itching, burning, and skin pain by week 16. About 64% of patients achieved nearly clear skin at this time. Another study found that guselkumab helped most adults with moderate plaque psoriasis, even when it affected a small area of their body, to achieve clear or almost clear skin. This treatment demonstrated meaningful improvements in disease activity and patient-reported outcomes over 9–12 months. Overall, guselkumab consistently delivers strong results in clearing skin and reducing psoriasis symptoms.12678
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for individuals with a diagnosis of moderate plaque psoriasis covering a low area of the body, who haven't responded well to or can't tolerate at least one topical treatment. They should be eligible for light therapy or systemic treatment and have had psoriasis for over six months. People with non-plaque psoriasis, drug-induced psoriasis, certain palmoplantar conditions, previous biologic treatments, or chronic infections cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive guselkumab or placebo by subcutaneous injection
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Guselkumab
- Placebo
Trial Overview
The study aims to compare the effectiveness of Guselkumab (a medication) against a placebo (an inactive substance) in treating patients with moderate plaque psoriasis affecting small areas of their body including special sites like palms and soles.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive guselkumab by subcutaneous injection with placebo as needed to maintain the blind.
Participants will receive placebo by subcutaneous injection then receive guselkumab by subcutaneous injection.
Guselkumab is already approved in United States, European Union for the following indications:
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Moderately to severely active ulcerative colitis
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Moderately to severely active ulcerative colitis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University
Citations
study results
In clinical studies, at 16 weeks, patients had improvements in symptoms of plaque psoriasis including itching, burning, pain, stinging, and skin tightness.
Effectiveness of Guselkumab Therapy among Patients with ...
The results show that 9–12 months of guselkumab treatment is associated with meaningful improvements in numerous assessments of disease activity and PROMs in a ...
Skin Clearance Data: Moderate to Severe Plaque PsO
Clearer skin is possible · 64% (102/160) of patients receiving TREMFYA® achieved PASI 90 response at Week 16 · 71% (113/160) of patients receiving TREMFYA® ...
New SPECTREM study findings reveal TREMFYA® ...
Treatment with TREMFYA (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis ...
5.
jnjmedicalconnect.com
jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-efficacy-outcomes-by-weight-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritisTREMFYA - Efficacy Outcomes by Weight in Adult Patients ...
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study ...
Safety of guselkumab treatment for up to 5 years in patients ...
Guselkumab has demonstrated favourable safety and efficacy across individual clinical studies in adults with moderate-to-severe plaque psoriasis.
guselkumab efficacy and safety for the treatment of low body ...
Our results show that clear or almost clear skin in all body regions was achieved in most people with psoriasis after three doses of guselkumab.
Guselkumab for Moderate to Severe Psoriasis Across All ...
This randomized clinical trial evaluates the efficacy, quality of life, and adverse event outcomes of guselkumab, 100 mg, among patients ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.